Answering human papillomavirus vaccine concerns; A matter of science and time

Infectious Agents and Cancer

Volumn 8, Issue 1, 2013, Pages

  Hawkes, David ^a   Lea, Candice E ^b   Berryman, Matthew J ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

Adverse events; Cancer prevention; Cervical cancer; Clinical trials; HPV; Human papillomavirus; Safety

Indexed keywords

PLACEBO; WART VIRUS VACCINE;

AUTOIMMUNE DISEASE; CANCER RISK; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; NAUSEA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; UTERINE CERVIX CANCER; VACCINATION;

EID: 84878817411     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-8-22     Document Type: Review

References (49)

1. HPV vaccination mandates-lawmaking amid political and scientific controversy. Colgrove J, Abiola S, Mello MM, N Engl J Med 2010 363 8 785 791 10.1056/NEJMsr1003547 20818883
2. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. Future II Study Group, N Engl J Med 2007 356 19 1915 1927 17494925
3. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G, Lancet 2004 364 9447 1757 1765 10.1016/S0140-6736(04)17398-4 15541448 (Pubitemid 39488060)
4. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, Olsson SE, Hoye J, Steinwall M, Riis-Johannessen G, Andersson-Ellstrom A, Elfgren K, Krogh G, Lehtinen M, Malm C, Tamms GM, Giacoletti K, Lupinacci L, Railkar R, Taddeo FJ, Bryan J, Esser MT, Sings HL, Saah AJ, Barr E, Br J Cancer 2006 95 11 1459 1466 10.1038/sj.bjc.6603469 17117182 (Pubitemid 44863348)
5. Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste Costa Rica. Herrero R, Wacholder S, Rodriguez AC, Solomon D, Gonzalez P, Kreimer AR, Porras C, Schussler J, Jimenez S, Sherman ME, Quint W, Schiller JT, Lowy DR, Schiffman M, Hildesheim A, Cancer Discov 2011 1 5 408 419 10.1158/2159-8290.CD-11-0131 22586631
6. A review of clinical trials of human papillomavirus prophylactic vaccines. Schiller JT, Castellsague X, Garland SM, Vaccine 2012 30 Suppl 5 123 F138 23199956
7. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsague X, Skinner SR, Apter D, Naud P, Salmeron J, Chow SN, Kitchener H, Teixeira JC, Hedrick J, Limson G, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, De Carvalho NS, Germar MJ, Peters K, Mindel A, De Sutter P, Bosch FX, David MP, Descamps D, Struyf F, Dubin G, Lancet Oncol 2012 13 1 89 99 10.1016/S1470-2045(11)70286-8 22075171
8. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Dillner J, Joura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, et al. Cancer Prev Res (Phila) 2009 2 10 868 878 10.1158/1940-6207.CAPR-09-0031
9. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence. Kjaer SK, Frederiksen K, Munk C, Iftner T, J Natl Cancer Inst 2010 102 19 1478 1488 10.1093/jnci/djq356 20841605
10. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. Munoz N, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia PJ, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Huh WK, Joura EA, Kurman RJ, Majewski S, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al. J Natl Cancer Inst 2010 102 5 325 339 10.1093/jnci/djp534 20139221
11. Epidemiologic classification of human papillomavirus types associated with cervical cancer. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, N Engl J Med 2003 348 6 518 527 10.1056/NEJMoa021641 12571259 (Pubitemid 36159887)
12. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. Group FIIS, Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Lehtinen M, Steben M, Bosch FX, Joura EA, Majewski S, Munoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, et al. BMJ 2010 341 3493 20647284
13. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste. Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C, Solomon D, Gonzalez P, Porras C, Jimenez S, Guillen D, Morales J, Alfaro M, Cyr J, Morrisey K, Estrada Y, Cortes B, Morera LA, Freer E, Schussler J, Schiller J, Lowy D, Schiffman M, Costa Rica Vaccine Trial G, Costa Rica. Vaccine 2008 26 37 4795 4808
14. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Roteli-Martins CM, Naud P, De Borba P, Teixeira JC, De Carvalho NS, Zahaf T, Sanchez N, Geeraerts B, Descamps D, Hum Vaccin Immunother 2010 8 3 390 397
15. Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6.4 years. Romanowski B, de Borba PC, Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, Aoki F, Ramjattan B, Shier RM, Somani R, Barbier S, Blatter MM, Chambers C, Ferris D, Gall SA, Guerra FA, Harper DM, Hedrick JA, Henry DC, Korn AP, Kroll R, Moscicki AB, Rosenfeld WD, Sullivan BJ, Thoming CS, Tyring SK, Wheeler CM, Dubin G, Schuind A, Zahaf T, et al. Lancet 2009 374 9706 1975 1985 19962185
16. Occurrence of vaccine and non-vaccine human papillomavirus types in adolescent Finnish females 4 years post-vaccination. Palmroth J, Merikukka M, Paavonen J, Apter D, Eriksson T, Natunen K, Dubin G, Lehtinen M, Int J Cancer 2012 131 12 2832 2838 10.1002/ijc.27586 22492244
17. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. Weinberg A, Song LY, Saah A, Brown M, Moscicki AB, Meyer WA 3rd, Bryan J, Levin MJ, J Infect Dis 2012 206 8 1309 1318 10.1093/infdis/jis489 22859825
18. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. Joura EA, Garland SM, Paavonen J, Ferris DG, Perez G, Ault KA, Huh WK, Sings HL, James MK, Haupt RM, BMJ 2012 344 1401 10.1136/bmj.e1401 22454089
19. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS, Am J Epidemiol 2008 168 2 123 137 10.1093/aje/kwn036 18483125 (Pubitemid 351951589)
20. Persistence of an incident human papillomavirus infection and timing of cervical lesions in previously unexposed young women. Trottier H, Mahmud SM, Lindsay L, Jenkins D, Quint W, Wieting SL, Schuind A, Franco EL, Cancer Epidemiol Biomarkers Prev 2009 18 3 854 862 10.1158/1055-9965.EPI-08-1012 19223559
21. Effect of a mass screening program on the risk of cervical cancer. Hakama M, Rasanen-Virtanen U, Am J Epidemiol 1976 103 5 512 517 1274953
22. Natural history of cervical intraepithelial neoplasia: a critical review. Ostor AG, Int J Gynecol Pathol 1993 12 2 186 192 10.1097/00004347-199304000- 00018 8463044 (Pubitemid 23095196)
23. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Katki HA, Kinney WK, Fetterman B, Lorey T, Poitras NE, Cheung L, Demuth F, Schiffman M, Wacholder S, Castle PE, Lancet Oncol 2011 12 7 663 672 10.1016/S1470-2045(11)70145-0 21684207
24. Rate of and risks for regression of cervical intraepithelial neoplasia 2 in adolescents and young women. Moscicki AB, Ma Y, Wibbelsman C, Darragh TM, Powers A, Farhat S, Shiboski S, Obstet Gynecol 2010 116 6 1373 1380 10.1097/AOG.0b013e3181fe777f 21099605
25. Chromosomal amplifications, 3q gain and deletions of 2q33-q37 are the frequent genetic changes in cervical carcinoma. Rao PH, Arias-Pulido H, Lu XY, Harris CP, Vargas H, Zhang FF, Narayan G, Schneider A, Terry MB, Murty VV, BMC Cancer 2004 4 5 10.1186/1471-2407-4-5 15018632 (Pubitemid 38851368)
26. Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Munger K, Scheffner M, Huibregtse JM, Howley PM, Cancer Surv 1992 12 197 217 1322242
27. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N, J Pathol 1999 189 1 12 19 10.1002/(SICI)1096-9896(199909)189:1<12::AID-PATH431>3.0.CO;2-F 10451482 (Pubitemid 29406813)
28. Hallmarks of cancer: the next generation. Hanahan D, Weinberg RA, Cell 2011 144 5 646 674 10.1016/j.cell.2011.02.013 21376230
29. Molecular biology of cervical cancer and its precursors. Park TW, Fujiwara H, Wright TC, Cancer 1995 76 10 Suppl 1902 1913 8634981
30. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Kjaer S, Hogdall E, Frederiksen K, Munk C, van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T, Cancer Res 2006 66 21 10630 10636 10.1158/0008-5472.CAN-06- 1057 17062559 (Pubitemid 44799787)
31. A population-based study of squamous cell vaginal cancer: HPV and cofactors. Daling JR, Madeleine MM, Schwartz SM, Shera KA, Carter JJ, McKnight B, Porter PL, Galloway DA, McDougall JK, Tamimi H, Gynecol Oncol 2002 84 2 263 270 10.1006/gyno.2001.6502 11812085 (Pubitemid 34136778)
32. The global health burden of infection-associated cancers in the year 2002. Parkin DM, Int J Cancer 2006 118 12 3030 3044 10.1002/ijc.21731 16404738
33. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ, BMJ 2013 346 2032 10.1136/bmj.f2032 23599298
34. Vaccine components and constituents: responding to consumer concerns. Eldred BE, Dean AJ, McGuire TM, Nash AL, Med J Aust 2006 184 4 170 175 16489901
35. Analysis of adverse events of potential autoimmune aetiology in a large integrated safety database of AS04 adjuvanted vaccines. Verstraeten T, Descamps D, David M-P, Zahaf T, Hardt K, Izurieta P, Dubin G, Breuer T, Vaccine 2008 26 51 6630 6638 10.1016/j.vaccine.2008.09.049 18845199
36. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Block SL, Brown DR, Chatterjee A, Gold MA, Sings HL, Meibohm A, Dana A, Haupt RM, Barr E, Tamms GM, Zhou H, Reisinger KS, Pediatr Infect Dis J 2010 29 2 95 101 10.1097/INF.0b013e3181b77906 19952863
37. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. Pomfret TC, Gagnon JM Jr, Gilchrist AT, J Clin Pharm Ther 2011 36 1 1 9 10.1111/j.1365-2710.2009.01150.x 21198715
38. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. Lu B, Kumar A, Castellsague X, Giuliano AR, BMC Infect Dis 2011 11 13 10.1186/1471-2334-11-13 21226933
39. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Mao C, Koutsky LA, Ault KA, Wheeler CM, Brown DR, Wiley DJ, Alvarez FB, Bautista OM, Jansen KU, Barr E, Obstet Gynecol 2006 107 1 18 27 10.1097/01.AOG.0000192397.41191.fb 16394035
40. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Munoz N, Manalastas R Jr, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A, Lancet 2009 373 9679 1949 1957 10.1016/S0140-6736(09)60691-7 19493565
41. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, Skjeldestad FE, Olsson SE, Steinwall M, Brown DR, Kurman RJ, Ronnett BM, Stoler MH, Ferenczy A, Harper DM, Tamms GM, Yu J, Lupinacci L, Railkar R, Taddeo FJ, Jansen KU, Esser MT, Sings HL, Saah AJ, Barr E, Lancet Oncol 2005 6 5 271 278 10.1016/S1470-2045(05)70101-7 15863374
42. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Gold MS, McIntyre P, Sex Health 2010 7 3 320 324 10.1071/SH09153 20719221
43. Human papillomavirus vaccine safety in pediatric patients: an evaluation of the Vaccine Adverse Event Reporting System. Borja-Hart NL, Benavides S, Christensen C, Ann Pharmacother 2009 43 2 356 359 19155346
44. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J, JAMA 2009 302 7 750 757 10.1001/jama.2009.1201 19690307
45. Human papilloma virus immunization in adolescent and young adults: a cohort study to illustrate what events might be mistaken for adverse reactions. Siegrist CA, Lewis EM, Eskola J, Evans SJ, Black SB, Pediatr Infect Dis J 2007 26 11 979 984 10.1097/INF.0b013e318149dfea 17984802 (Pubitemid 350287577)
46. U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee (VRBPAC), VRBPAC Background Document: Gardasil™ HPV Quadrivalent Vaccine. May 18, 2006 VRBPAC Meeting http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4222B3.pdf
47. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine coadministered with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine and/or meningococcal conjugate vaccine to healthy girls 11 to 18 years of age: results from a randomized open trial. Wheeler CM, Harvey BM, Pichichero ME, Simon MW, Combs SP, Blatter MM, Marshall GS, Catteau G, Dobbelaere K, Descamps D, Dubin G, Schuind A, Pediatr Infect Dis J 2011 30 12 225 e234 10.1097/INF.0b013e31822d28df 21817954
48. Randomized trial: immunogenicity and safety of coadministered human papillomavirus-16/18 AS04-adjuvanted vaccine and combined hepatitis A and B vaccine in girls. Pedersen C, Breindahl M, Aggarwal N, Berglund J, Oroszlan G, Silfverdal SA, Szuts P, O'Mahony M, David MP, Dobbelaere K, Dubin G, Descamps D, J Adolesc Health 2012 50 1 38 46 10.1016/j.jadohealth.2011.10.009 22188832
49. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Arbyn M, Ronco G, Anttila A, Meijer CJ, Poljak M, Ogilvie G, Koliopoulos G, Naucler P, Sankaranarayanan R, Peto J, Vaccine 2012 30 Suppl 5 88 F99 23199969